Emapalumab, a fully human IgG1 monoclonal antibody targeting IFN-γ, has been proposed to have clinical benefit in CRS.<h4>Methods</h4>In this retrospective study, we conducted a comprehensive analysis of clinical and laboratory parameters in 38 pediatric patients who failed low-dose glucocorticoids monotherapy, tocilizumab monotherapy or glucocorticoid-tocilizumab combination therapy, following treatment with investigational CAR-T products.<h4>Results</h4>Emapalumab significantly improved both clinical symptoms and laboratory parameters. The gene discussed is IFNG; the disease is congenital rubella syndrome.